Guangzhou Baiyunshan Pharmaceutical Stock Fundamentals
GU5 Stock | EUR 2.14 0.04 1.90% |
Guangzhou Baiyunshan Pharmaceutical fundamentals help investors to digest information that contributes to Guangzhou Baiyunshan's financial success or failures. It also enables traders to predict the movement of Guangzhou Stock. The fundamental analysis module provides a way to measure Guangzhou Baiyunshan's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Guangzhou Baiyunshan stock.
Guangzhou |
Guangzhou Baiyunshan Pharmaceutical Company Profit Margin Analysis
Guangzhou Baiyunshan's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Guangzhou Baiyunshan Profit Margin | 0.06 % |
Most of Guangzhou Baiyunshan's fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Guangzhou Baiyunshan Pharmaceutical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
Competition |
Based on the latest financial disclosure, Guangzhou Baiyunshan Pharmaceutical has a Profit Margin of 0.0552%. This is 100.49% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The profit margin for all Germany stocks is 104.35% lower than that of the firm.
Guangzhou Baiyunshan Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Guangzhou Baiyunshan's current stock value. Our valuation model uses many indicators to compare Guangzhou Baiyunshan value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Guangzhou Baiyunshan competition to find correlations between indicators driving Guangzhou Baiyunshan's intrinsic value. More Info.Guangzhou Baiyunshan Pharmaceutical is rated # 4 in return on equity category among its peers. It is rated below average in return on asset category among its peers reporting about 0.28 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Guangzhou Baiyunshan Pharmaceutical is roughly 3.60 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Guangzhou Baiyunshan's earnings, one of the primary drivers of an investment's value.Guangzhou Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Guangzhou Baiyunshan's direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Guangzhou Baiyunshan could also be used in its relative valuation, which is a method of valuing Guangzhou Baiyunshan by comparing valuation metrics of similar companies.Guangzhou Baiyunshan is rated below average in profit margin category among its peers.
Guangzhou Fundamentals
Return On Equity | 0.13 | |||
Return On Asset | 0.0356 | |||
Profit Margin | 0.06 % | |||
Operating Margin | 0.05 % | |||
Current Valuation | 5.35 B | |||
Shares Outstanding | 219.9 M | |||
Shares Owned By Institutions | 34.00 % | |||
Price To Earning | 8.09 X | |||
Price To Book | 1.07 X | |||
Price To Sales | 0.1 X | |||
Revenue | 69.01 B | |||
Gross Profit | 13.19 B | |||
EBITDA | 5.46 B | |||
Net Income | 3.72 B | |||
Cash And Equivalents | 21.69 B | |||
Cash Per Share | 13.34 X | |||
Total Debt | 752.81 M | |||
Debt To Equity | 0.36 % | |||
Current Ratio | 1.64 X | |||
Book Value Per Share | 19.33 X | |||
Cash Flow From Operations | 5.67 B | |||
Earnings Per Share | 0.33 X | |||
Number Of Employees | 25.44 K | |||
Beta | 0.7 | |||
Market Capitalization | 6.7 B | |||
Total Asset | 66.12 B | |||
Z Score | 5.8 | |||
Annual Yield | 0.04 % | |||
Net Asset | 66.12 B | |||
Last Dividend Paid | 0.69 |
About Guangzhou Baiyunshan Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Guangzhou Baiyunshan Pharmaceutical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Guangzhou Baiyunshan using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Guangzhou Baiyunshan Pharmaceutical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited engages in the research, development, manufacture, and sale of Chinese patent and Western medicines, chemical raw materials, natural and biological medicines, and chemical raw material intermediates in the Peoples Republic of China and internationally. Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited was incorporated in 1997 and is based in Guangzhou, China. GUANG BAIY operates under Drug ManufacturersSpecialty Generic classification in Germany and is traded on Frankfurt Stock Exchange. It employs 25168 people.
Currently Active Assets on Macroaxis
Other Information on Investing in Guangzhou Stock
Guangzhou Baiyunshan financial ratios help investors to determine whether Guangzhou Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Guangzhou with respect to the benefits of owning Guangzhou Baiyunshan security.